Abstract
References
Articles referenced by this article (11)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Leukemia, (11):2398-2406 2017
MED: 28804124
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Blood, (4):494-500 2013
MED: 24311723
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
Leukemia, (10):2197-2203 2012
MED: 22699418
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
N Engl J Med, (19):1783-1796 2013
MED: 24180494
The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors.
Hematology Am Soc Hematol Educ Program, (1):170-179 2016
MED: 27913477
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
J Clin Oncol, (16):1875-1880 2024
MED: 38471049
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Lancet Haematol, (7):e375-e383 2019
MED: 31201085
Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML.
Blood, (10):766-769 2020
MED: 31935278
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
Haematologica, (12):2738-2745 2020
MED: 33054106
Show 1 more reference (10 of 11)
Citations & impact
This article has not been cited yet.
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Funding
Funders who supported this work.
Blood Cancer UK (2)
Targeting abnormal control of cell division and quiescence to eliminate leukaemic stem cells
Professor Mhairi Copland, University of Glasgow
Grant ID: 11017
publications
DESTINY: a trial of de-escalation and stopping treatment in CML patients with excellent responses to tyrosine kinase inhibitor therapy
Professor Richard Clark, University of Liverpool
Grant ID: 13020
publications
Cancer Research UK (1)
Grant ID: CRCPJT/100006
publications
